Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma por Perla Pucci, Liam C. Lee, Miaojun Han, Jamie D. Matthews, Leila Jahangiri, Michaela Schlederer, Eleanor Manners, Annabel Sorby-Adams, Joshua Kaggie, Ricky M. Trigg, Christopher Steel, Lucy Hare, Emily R. James, Nina Prokoph, Stephen P. Ducray, Olaf Merkel, Firkret Rifatbegovic, Ji Luo, Sabine Taschner-Mandl, Lukas Kenner, G. A. Amos Burke, Suzanne D. Turner

Obter o texto integral